Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CKD-843 in Male Patients With Androgenetic Alopecia
NCT06916793Phase 3Recruiting
- Sponsor
- Chong Kun Dang Holdings
- Start
- Apr 2025
- Primary completion
- Sep 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of CKD-843 in androgenetic alopecia (AGA) (4 arms), sponsored by Chong Kun Dang Holdings. Primary endpoint: Total number of hair Changes at 24 weeks. Started Apr 2025; status: recruiting.
02
Drugs
CKD-843
03
Conditions
androgenetic alopecia (AGA)
Beyond the preview
Go deeper on NCT06916793.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06916793.